Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 339-344

  Van Kesteren, Charlotte ^a   Benders, Manon J N L ^b   Groenendaal, Floris ^b   Van Bel, Frank ^b   Ververs, F F Tessa ^a   Rademaker, Carin M A ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Allopurinol; Birth asphyxia; Neonates; Population pharmacokinetics

Indexed keywords

ALLOPURINOL;

ARTICLE; BRAIN DAMAGE; CLINICAL ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CRITICAL ILLNESS; DATA ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; HUMAN; NEWBORN; PERINATAL ASPHYXIA; POPULATION MODEL; PRIORITY JOURNAL; REPERFUSION INJURY; VALIDATION STUDY;

ALLOPURINOL; ASPHYXIA NEONATORUM; CLINICAL TRIALS; DOUBLE-BLIND METHOD; FREE RADICAL SCAVENGERS; HUMANS; INFANT, NEWBORN; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL;

EID: 33748154098     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211808.74192.86     Document Type: Article

References (19)

1. Levene ML, Kornberg J, Williams THC. The incidence and sevirity of post-asphyxial encephalopathy in full-term infants. Early Hum Dev. 1985;11:21-26.
2. Volpe JJ. Hypoxic-ischemic encephalopathy: clinical aspects. In: Volpe JJ ed. Neurology of the Newborn. 3rd edn. Philadelphia: WB Saunders, 1994:314-369.
3. Mc Cord JM. Oxygen-derived free radicals in post-ischemic tissue injury. N Engl J Med. 1985;312:159-163.
4. Peeters C, van Bel F. Pharmacotherapeutical reduction of posthypoxic-ischemic brain injury in the newborn. Biol Neonate. 2001;79:274-280.
5. Van Bel F, Shadid M, Moison RMW, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics. 1998;101:185-193.
6. Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxic ischemic brain damage with allopurinol. Pediatr Res. 1990;27:332-336.
7. Boda D, Németh I, Kiss P, et al. Treatment of mothers with allopurinol to produce therapeutic blood levels in newborns. Prenat Neonate Med. 1999;4:130-134.
8. Murrel GAC, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986;11:343-353.
9. Day RO, Birkett DJ, Hicks M, et al. New uses for allopurinol. Drugs. 1994;48:339-344.
10. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med. 1984;76:47-56.
11. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics fo allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999;48:501-509.
12. Mc Gaurn PS, Davis LE, Krawczeniuk MM, et al. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome. Pediatrics. 1994;94:820-823.
13. Beal SL, Boeckman AJ, Sheiner LB. NONMEM: User's Guides, University of California at San Francisco, San Francisco CA; 1988-1992.
14. Ette E, Ludden T. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res. 1995;12:1845-1855.
15. Ette E. Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial. Ann Pharmacother. 1998;32:818-828.
16. Jonsson EN, Karlsson MO. Xpose- an S-PLUS based model building aid for population analysis with NONMEM. Comp Meth Prog Biomed. 1999;58:51-64.
17. Karlsson MO, Jonsson EN, Wiltse CG, et al. Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients. J Pharmacokinet Biopharm. 1998;26:207-246.
18. Department of Health and Human Services, Food and Drug administration: Guidance for Industry, Population Pharmacokinetics, 1999. Available at: http://www.fda.gov/cder/guidance/index.htm.
19. Ette E. Stability and predictive performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37:486-495.